Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of a significant decrease in short interest during the month of September. As of September 29th, there was short interest totalling 31,216,474 shares, a decrease of 10.0% from the September 15th total of 34,667,755 shares. Approximately 19.6% of the company’s shares are sold short. Based on an average daily volume of 4,218,265 shares, the short-interest ratio is presently 7.4 days.

Several equities research analysts have recently commented on FOLD shares. J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. BidaskClub downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Chardan Capital reaffirmed a “buy” rating and set a $16.50 target price (down from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Finally, Robert W. Baird upped their target price on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $17.81.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its holdings in Amicus Therapeutics by 3,672.2% during the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock worth $685,000 after acquiring an additional 66,209 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Amicus Therapeutics by 5.7% during the first quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock worth $5,541,000 after acquiring an additional 41,711 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in Amicus Therapeutics during the second quarter worth about $1,057,000. Geode Capital Management LLC raised its holdings in Amicus Therapeutics by 4.7% during the first quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock worth $8,323,000 after acquiring an additional 52,003 shares in the last quarter. Finally, Morgan Stanley raised its holdings in Amicus Therapeutics by 99.4% during the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after acquiring an additional 3,055,039 shares in the last quarter.

Shares of Amicus Therapeutics (NASDAQ FOLD) opened at 14.25 on Friday. The stock’s 50 day moving average price is $14.31 and its 200-day moving average price is $10.80. The stock’s market capitalization is $2.35 billion. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The business had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. Equities research analysts anticipate that Amicus Therapeutics will post ($1.32) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/13/short-interest-in-amicus-therapeutics-inc-fold-drops-by-10-0.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.